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Abstract
Background
In 2015, approximately 42,000 women died as a result of hypertensive disorders of preg-
nancy worldwide; over 99% of these deaths occurred in low- and middle-income countries.
The aim of this paper is to describe the incidence and characteristics of eclampsia and
related complications from hypertensive disorders of pregnancy across 10 low- and middle-
income geographical regions in 8 countries, in relation to magnesium sulfate availability.
Methods and findings
This is a secondary analysis of a stepped-wedge cluster randomised controlled trial under-
taken in sub-Saharan Africa, India, and Haiti. This trial implemented a novel vital sign device
and training package in routine maternity care with the aim of reducing a composite outcome
of maternal mortality and morbidity. Institutional-level consent was obtained, and all women
presenting for maternity care were eligible for inclusion. Data on eclampsia, stroke, admis-
sion to intensive care with a hypertensive disorder of pregnancy, and maternal death from a
hypertensive disorder of pregnancy were prospectively collected from routine data sources
and active case finding, together with data on perinatal outcomes in women with these out-
comes. In 536,233 deliveries between 1 April 2016 and 30 November 2017, there were
2,692 women with eclampsia (0.5%). In total 6.9% (n = 186; 3.47/10,000 deliveries) of
women with eclampsia died, and a further 51 died from other complications of hypertensive
disorders of pregnancy (0.95/10,000). After planned adjustments, the implementation of the
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CRADLE intervention was not associated with any significant change in the rates of eclamp-
sia, stroke, or maternal death or intensive care admission with a hypertensive disorder of
pregnancy. Nearly 1 in 5 (17.9%) women with eclampsia, stroke, or a hypertensive disorder
of pregnancy causing intensive care admission or maternal death experienced a stillbirth or
neonatal death. A third of eclampsia cases (33.2%; n = 894) occurred in women under 20
years of age, 60.0% in women aged 20–34 years (n = 1,616), and 6.8% (n = 182) in women
aged 35 years or over. Rates of eclampsia varied approximately 7-fold between sites (range
19.6/10,000 in Zambia Centre 1 to 142.0/10,000 in Sierra Leone). Over half (55.1%) of first
eclamptic fits occurred in a health-care facility, with the remainder in the community. Place
of first fit varied substantially between sites (from 5.9% in the central referral facility in Sierra
Leone to 85% in Uganda Centre 2). On average, magnesium sulfate was available in 74.7%
of facilities (range 25% in Haiti to 100% in Sierra Leone and Zimbabwe). There was no
detectable association between magnesium sulfate availability and the rate of eclampsia
across sites (p = 0.12). This analysis may have been influenced by the selection of predomi-
nantly urban and peri-urban settings, and by collection of only monthly data on availability of
magnesium sulfate, and is limited by the lack of demographic data in the population of
women delivering in the trial areas.
Conclusions
The large variation in eclampsia and maternal and neonatal fatality from hypertensive disor-
ders of pregnancy between countries emphasises that inequality and inequity persist in
healthcare for women with hypertensive disorders of pregnancy. Alongside the growing
interest in improving community detection and health education for these disorders, efforts
to improve quality of care within healthcare facilities are key. Strategies to prevent eclamp-
sia should be informed by local data.
Trial registration
ISRCTN: 41244132.
Author summary
Why was this study done?
• High blood pressure in pregnancy affects nearly 1 in 7 pregnant women worldwide.
• Failure to recognise and treat this condition with antihypertensives, magnesium sulfate,
and delivery of the baby can result in serious complications for the mother and baby
such as eclampsia, intensive care admission, and death.
• In high-resource settings, severe complications are rare. In low-resource settings, they
are known to be more common, but their frequency and impact are not as well
reported.
Eclampsia in low and middle-resource countries
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What did the researchers do and find?
• We undertook a trial introducing a novel device that measures heart rate and blood
pressure into routine maternity care in 10 geographical areas in 8 countries in sub-Saha-
ran Africa, Haiti, and India, with the aim of reducing severe pregnancy complications
and death.
• In this study, we analysed all the women who experienced eclampsia or stroke or were
admitted to intensive care or had a maternal death as a result of high blood pressure in
pregnancy. In total, 0.5% of women experienced eclampsia (n = 2,692), 6.9% of these
women died (n = 186), and 15.9% of their babies died (n = 397). There was substantial
variation in eclampsia across different geographical regions, ranging from 0.20% to
1.42%.
• Nearly a third of eclampsia occurred in women aged under 20 years, but this proportion
differed between geographical regions, ranging from 9.9% to 50.1%.
• More than half (55.1%) of women experienced their first eclamptic fit in a healthcare
facility, but this proportion also differed between regions, with 6% to 85% of first
eclamptic fits occurring in a central referral facility.
What do these findings mean?
• This is one of the largest studies of eclampsia to date and confirms that high blood pres-
sure in pregnancy remains an important cause of morbidity and mortality in low-
resource countries.
• The majority of our geographical areas were urban or peri-urban and contained a large
tertiary hospital. This means that more women with high blood pressure in pregnancy
may be referred to these sites, so the rates may be higher than in the country as a whole.
• Understanding place of first eclamptic fit (in the community or in small or large tertiary
facilities) may be useful in targeting interventions to reduce eclampsia, focusing either
on community interventions or quality of facility care.
Introduction
Hypertensive disorders of pregnancy cause 14% of all maternal deaths globally, approximately
42,000 each year [1,2]. Nearly all of these deaths occur in low-resource settings (99%), with
death in high-income settings being very rare [3]. Hypertensive disorders of pregnancy
encompass chronic hypertension, gestational hypertension (new hypertension without pro-
teinuria), pre-eclampsia (new hypertension with proteinuria or end-organ damage after 20
weeks of gestation [4]), and eclampsia. The majority of morbidity and mortality is associated
with pre-eclampsia and eclampsia.
It is estimated that the prevalence of pre-eclampsia globally is 4.6% (95% CI 2.7%–8.2%)
[5]. The prevalence of eclampsia globally is reported to be 0.3% [6]. This is based on secondary
analysis of a World Health Organization (WHO) multi-country survey that included 875 cases
Eclampsia in low and middle-resource countries
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of eclampsia, collected over a short duration from only secondary or tertiary hospitals [6].
Women under 20 years of age, women with low levels of education, and women in their first
pregnancy are all reported to be at higher risk [6]. Reliable data reporting the prevalence of
maternal deaths related to eclampsia globally are scarce. Estimates from 16 datasets reported
the case fatality rate to be 8.3% [5], whereas the WHO survey reported 32 maternal deaths,
3.7% of women with eclampsia [6]. Data from individual countries suggest that prevalence and
mortality risk vary depending on region and socio-economic status [7].
Administration of magnesium sulfate more than halves the risk of eclampsia in women
with pre-eclampsia [8]. It is considered an essential drug by WHO [9], but data on its availabil-
ity in relation to prevalence of eclampsia are scarce [5]. Planned delivery after 36 weeks of ges-
tation is effective at preventing maternal morbidity in women with pre-eclampsia [10].
Evidence for other interventions effective at reducing morbidity and mortality of pre-eclamp-
sia is mixed [11], and research is generally undertaken in high-income settings, where the bur-
den of illness is small. There is a lack of understanding around modifiable risk factors and
availability of life-saving interventions, both vital in reducing the high number of deaths from
this treatable cause.
The aim of this paper is to describe the incidence (per pregnancy) and characteristics of
eclampsia, stroke, maternal death from hypertensive disorders of pregnancy, and intensive
care unit (ICU) admission from hypertensive disorders of pregnancy across 10 geographical
regions in 8 low- and middle-resource countries. The secondary aim is to describe the effect of
a novel vital sign device and educational package on eclampsia, stroke, maternal death from a
hypertensive disorder of pregnancy, or ICU admission with a hypertensive disorder of
pregnancy.
Methods
Study design and setting
This is a secondary analysis of a pragmatic, stepped-wedge cluster randomised controlled trial
of the introduction of the CRADLE intervention (described below) into routine maternity
care in 10 sites across Zimbabwe, Zambia, Sierra Leone, Malawi, Ethiopia, Uganda, Haiti, and
India over 20 months from 1 April 2016 to 30 November 2017 (ISCRTN41244132) [12,13].
The stepped-wedge design means that at the trial start all clusters commenced data collection;
all clusters then crossed from control to intervention at a randomly allocated time point, at
2-monthly intervals, until all had received the intervention. The intervention effect was then
determined by comparing the data points after delivery of the intervention with those in the
control period. Each site comprised at least 1 secondary or tertiary hospital that provided com-
prehensive emergency obstetric care (central referral facility) and the main peripheral facilities
that referred to the central referral facility. All secondary and tertiary hospitals were urban or
peri-urban, but the geographical regions of peripheral facilities covered a range of settings,
with the mean distance to the central referral facility varying from 3.3 km to 74 km. The inter-
vention was delivered to all healthcare professionals working in the site facilities. Community
healthcare providers received the intervention where they were formally involved in routine
maternity care provision and supported at the district level [12].
Intervention
The CRADLE intervention consisted of the CRADLE Vital Sign Alert, an accurate, easy-to-use
device that measures maternal blood pressure and heart rate and calculates shock index.
Results are displayed via a traffic light early warning system [14,15]. The devices were delivered
with a one-off interactive training session of CRADLE Champions, who then provided
Eclampsia in low and middle-resource countries
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ongoing training and support for use of the device in their clinical area. Further details of the
development of the CRADLE intervention have previously been described [12,16]. This inter-
vention was compared to routine maternity care using local management guidelines.
Study outcomes
The primary outcome of the overall trial was a composite outcome of maternal mortality and
morbidity (at least 1 of eclampsia, emergency hysterectomy, and maternal death) per 10,000
deliveries. In spite of a reduction in the primary outcome over time, this trial was unable to
demonstrate an effect of the intervention. For the purpose of the analysis reported here, all
women who presented to maternity care at any gestational age or up to 42 days after delivery
and were diagnosed with eclampsia or experienced a complication of a hypertensive disorder
of pregnancy (stroke, or being admitted to an ICU or dying as a result of a hypertensive disor-
der of pregnancy), between 1 April 2016 and 31 November 2017 were eligible for inclusion.
The denominator was all deliveries in the trial area in the same period. Eclampsia was defined
as convulsions with raised blood pressure in the absence of a known neurological cause during
pregnancy or within 42 days after delivery. Other data collected included maternal age at
eclamptic fit, timing of eclampsia (antenatal, including day of delivery, or postnatal), and the
place of first eclamptic fit (community, peripheral facility, or central referral facility). The
number of stillbirths and neonatal deaths up to 28 days was recorded for all women who had
antenatal eclampsia, had a stroke, or were admitted to ICU or died as a result of hypertensive
disorders of pregnancy.
Sites were described by the number of deliveries, number of ICU beds per 1,000 deliveries,
and the proportion of facilities (central referral and peripheral) where magnesium sulfate was
available. Availability of magnesium sulfate was recorded on a monthly basis. Details on the
quantity available daily or individual-level prescriptions were not collected. Methods of data
collection were discussed and optimised based on the existing resources available in each site.
All data collectors were given detailed training to ensure comparability of results. Outcomes
were triangulated across multiple sources (including referral registers, ward registers, patient
records, local mortality and morbidity records, and active case finding) to ensure data com-
pleteness, and all outcomes were checked to avoid double counting.
Ethics and consent
Ethical approval was granted by the Biomedical Sciences, Dentistry, Medicine and Natural and
Mathematical Sciences Research Ethics Subcommittee at King’s College London (LRS-14/15-
1484). This and all local ethical approvals were in place prior to the study start. Institutional-
level consent on behalf of the cluster was obtained.
Statistical methods and analysis
Statistical analyses were undertaken in Stata version 13.1. The main analysis used logistic
regression with generalised estimating equations and a population-averaged model, with fixed
centre effects and separate fixed linear trends in each site for changes in outcome over time
[17]. Results are reported as odds ratios with 95% confidence intervals. The trial protocol
stated that individual components of the primary outcome, including eclampsia, ICU admis-
sions, and maternal deaths, and place of eclamptic fit would be analysed. However, there was
no predefined analysis plan for this secondary analysis [12]. To describe the association
between eclampsia and magnesium sulfate availability, the eclampsia rates for each site time
period (month), and place of eclamptic fit were calculated. Eclamptic fits in the community
were excluded from these analyses as magnesium sulfate was not available in the community.
Eclampsia in low and middle-resource countries
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The analysis of the association between magnesium sulfate availability and total eclampsia by
site used linear regression of the log of eclampsia rate with robust standard errors. The analysis
of the association between magnesium sulfate availability and place of eclamptic fit used logis-
tic regression with robust standard errors. Adjustments were made for time period (linear)
and centre (categorical) to account for trends over time. Individual patient data were collected
only for known cases.
Results
In this cohort of 536,233 deliveries there were 2,692 cases of eclampsia over 20 months. This
gives an incidence of eclampsia of 0.5%, as shown in Table 1 (50.2/10,000 deliveries). In total,
6.9% (n = 186; 3.47/10,000 deliveries) of women with eclampsia died (sepsis [n = 4], stroke
[n = 4], haemorrhage [n = 18], hypertensive disorders of pregnancy [n = 150], and other causes
[n = 10]), and a further 51 women died from other complications of hypertensive disorders of
pregnancy without having had eclampsia (0.95/10,000). Eight of the 10 sites had capacity for
ICU admission, although availability of beds varied between sites (S1 Table). In total, 1,322
women were admitted to ICU with hypertensive disorders of pregnancy, 27.8% of these with
eclampsia (n = 367) and 72.2% (n = 955) with other complications of hypertensive disorders of
pregnancy. After planned adjustments for clustering and time trends in each site, the imple-
mentation of the CRADLE intervention was not associated with any significant change in the
rates of eclampsia, stroke, maternal death from a hypertensive disorder of pregnancy, or ICU
admission with a hypertensive disorder of pregnancy.
Rates of eclampsia varied between sites from 19.6 per 10,000 deliveries in Zambia Centre 1
(Lusaka) to 142.0 per 10,000 deliveries in Sierra Leone (Fig 1; S2 Table). When comparing the
effect of the intervention across individual sites, further consideration is required as these are
Table 1. Rates of eclampsia, stroke, and maternal death and intensive care unit admission as a result of hypertensive disorders of pregnancy, and effect of the CRA-
DLE intervention on outcomes.
Outcome Rate/10,000 deliveries; n/N Odds ratio (95% CI)
Overall Pre-intervention Post-intervention Unadjusted comparison Adjusted comparison1
All eclampsia 50.20
2,692/536,233
53.15
1,314/247,238
47.77
1,378/288,995
0.90 (0.83–0.97) 1.30 (0.82–2.05)
All maternal death from hypertensive
disorder of pregnancy2
4.42
237/536,233
3.84
95/247,238
4.91
142/288,995
1.28 (0.99–1.66) 0.84 (0.47–1.51)
Maternal death with eclampsia 3.47
186/536,233
2.87
71/247,238
3.98
115/288,995
1.39 (1.03–1.86) 0.79 (0.31–2.02)
Maternal death without eclampsia 0.95
51/536,233
0.97
24/247,238
0.93
27/288,995
0.96 (0.56–1.67) 1.06 (0.38–2.93)
ICU admission from hypertensive
disorder of pregnancy2
24.65
1,322/536,223
26.57
657/247,238
23.01
665/288,995
0.87 (0.78–0.96) 0.85 (0.72–1.02)
ICU admission with eclampsia 6.8
367/536,233
9.18
227/247,238
4.84
140/288,995
0.53 (0.43–0.65) 0.71 (0.38–1.33)
ICU admission without eclampsia 17.81
955/536,233
17.39
430/247,238
18.17
525/288,995
1.04 (0.92–1.19) 0.92 (0.87–0.96)
Stroke 0.62
33/536,233
0.85
21/247,238
0.42
12/288,995
0.49 (0.24–0.99) 2.08 (0.58–7.55)
1Adjusted for time period and centre to account for trends over time.
2All maternal death and ICU admission from hypertensive disorder of pregnancy include all cases resulting from hypertensive disorder of pregnancy, including those
with and without eclampsia. Both groups are then subdivided into those with eclampsia and those secondary to other complications of hypertensive disorders of
pregnancy without having eclampsia.
ICU, intensive care unit.
https://doi.org/10.1371/journal.pmed.1002775.t001
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non-randomised data and are vulnerable to external influences such as seasonal trends. After
planned adjustment, there was a significant reduction in eclampsia in Haiti and Zambia Cen-
tre 1, a significant increase in Malawi and Uganda Centre 2, and no significant changes in
other sites (S2 Table). The rate of maternal death from eclampsia in each site largely reflected
the incidence of eclampsia (from 0.4 per 10,000 deliveries in Zambia Centre 1 to 15.5 per
10,000 deliveries in Sierra Leone; S3 Table). The range of case fatality rate for women with
eclampsia was from 2.1% (5/242) in Zambia Centre 1 to 14.4% (18/125) in Haiti. Only 33 in
the cohort of 536,233 women were diagnosed with a stroke. ICU admission from hypertensive
disorders of pregnancy also varied between sites as shown in Fig 1 (S3 Table).
Across all sites, 92.7% (n = 2,495) of eclampsia cases occurred in the antenatal period and
7.3% (n = 197) in the postnatal period. The proportion of eclampsia cases occurring in the
antenatal period was similar across sites (range 88.9% in Uganda Centre 1 to 98.2% in Uganda
Centre 2) (Fig 2; S4 Table). Approximately a third of eclampsia cases (33.2%; n = 894) occurred
in women aged under 20 years. This proportion varied between sites from 10% in Ethiopia to
51% in Malawi (Fig 2; S4 Table). The majority of eclampsia cases occurred in women aged 20–
34 years (60.0%; n = 1,616); 6.8% (n = 182) occurred in women aged 35 years or over.
In total, there were 10 central referral facilities and 268 peripheral facilities. Nearly half of
all first eclamptic fits occurred in the community (44.9%; range 30.8% in Malawi to 66.0% in
Freetown; Table 2), with 31.2% occurring for the first time in central referral facilities (range
5.9% in Sierra Leone to 85.0% in Uganda Centre 2) and 23.9% in peripheral facilities (range
4.7% in India to 33.0% in Ethiopia). On average, magnesium sulfate was available in 74.7% of
facilities (range 25% in Haiti to 100% in Sierra Leone and Zimbabwe). Availability of magne-
sium sulfate did not significantly change during the trial period. There was no significant asso-
ciation between the overall availability of magnesium sulfate in central referral and peripheral
facilities and the proportion of eclampsia cases that occurred in each (central referral facilities:
p = 0.42; peripheral facilities: p = 0.13; Table 2). There was also no detectable association
between the proportion of facilities with magnesium sulfate available across the sites and the
rate of eclampsia in each site (p = 0.12). Of the 1,210 women who had their first eclamptic fit
in the community, 7.5% (91/1,210) died; of the 1,482 who had their first eclamptic fit in a facil-
ity, 6.4% (95/1,482) died.
In the group of 3,493 women with antenatal eclampsia (n = 2,495), stroke, or hypertensive
disorders of pregnancy causing ICU admission or maternal death (n = 998), the rate of still-
birth or neonatal mortality was very high (17.9%; n = 625). The rate of stillbirth or neonatal
mortality was higher in women with hypertensive disorders of pregnancy (i.e., resulting in
stroke, ICU admission, or maternal death) without eclampsia than in women with eclampsia
(stillbirth or neonatal death: 22.8% [n = 228] in women with hypertensive disorders of preg-
nancy without eclampsia and 15.9% [n = 397] in women with eclampsia; Table 3). Overall rate
of stillbirth or neonatal mortality in women with eclampsia varied between sites from 4.1% in
Malawi to 23.1% in Uganda Centre 1 (S5 Table).
Discussion
Overall, we report that 0.5% of women in our sites experienced eclampsia, 57.2% of women
with eclampsia were admitted to ICU, and 6.9% died. Our individual site analysis shows large
variation both in the rate of eclampsia and in the rates of maternal death and ICU admission
from hypertensive disorders of pregnancy. Stroke was a rare outcome in all of our sites. The
majority of eclampsia cases across all sites first occurred in the community (44.9%), in the
antenatal period (92.6%), and in women aged 20–34 years (60.0%). Overall, the implementa-
tion of the CRADLE intervention was not associated with any significant change in the rate of
Eclampsia in low and middle-resource countries
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Fig 1. Rates of eclampsia and maternal deaths and intensive care unit (ICU) admissions from hypertensive
disorders of pregnancy (HDP) by site. Data shown for eclampsia (A), maternal deaths from HDP (B), and ICU
admissions from HDP (C). ICU admissions shown for sites with ICU available. Corresponding numbers are given in
S2 and S3 Tables.
https://doi.org/10.1371/journal.pmed.1002775.g001
Fig 2. Characteristics of eclampsia by timing and maternal age by site. Data shown by timing of eclampsia (A) and
maternal age (B). Corresponding numbers are given in S4 Table.
https://doi.org/10.1371/journal.pmed.1002775.g002
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eclampsia, stroke, or maternal death or ICU admission with hypertensive disorders of preg-
nancy, but the effect in individual sites varied.
To our knowledge, this is the largest prospectively collected dataset on women with eclamp-
sia. The strengths of these data are the rigorous method of prospective data collection, verified
from multiple sources, and inclusion of multiple countries and settings. The majority of exist-
ing data have focused on eclampsia presenting to secondary or tertiary hospitals [6]. The data
presented here improve the accuracy of incidence estimates by including cases across the
health system, including cases from primary healthcare facilities and community cases.
Although the geographical settings of this study varied, it is a limitation of this study that
the majority of sites were urban or peri-urban. These settings were selected as a substantial
proportion of births occur in them. This approach, in addition to the inclusion of the national
referral hospital in many of our sites, means the incidence of complications from hypertensive
disorders of pregnancy in our sites may be higher than country-wide levels. Due to the size of
the study, it was not feasible to collect demographic data in the population of women who
delivered in the trial area. Therefore, the proportion of eclampsia cases in different age groups
and perinatal outcomes cannot be presented at the population level. Effects of the intervention
Table 2. Place of eclamptic fit and proportion of facilities with magnesium sulfate available on average over trial duration.
Site Total n n (percent of eclampsia cases) Mean magnesium sulfate availability over trial duration (%)
Central referral facility Peripheral facility Community
All sites 2,692 839 (31.2%) 643 (23.9%) 1,210 (44.9%) 74.7%
Ethiopia 203 57 (28.1%) 67 (33.0%) 79 (38.9%) 87.4%
Haiti 125 52 (41.6%) 16 (12.8%) 57 (45.6%) 25.0%
India 85 27 (31.8%) 4 (4.7%) 54 (63.5%) 95.4%
Malawi 666 242 (36.3%) 219 (32.9%) 205 (30.8%) 100.0%
Sierra Leone 338 20 (5.9%) 95 (28.1%) 223 (66.0%) 41.4%
Uganda Centre 1 559 161 (28.8%) 125 (22.4%) 273 (48.8%) 61.5%
Uganda Centre 2 167 142 (85.0%) 17 (10.2%) 8 (4.8%) 78.6%
Zambia Centre 1 242 34 (14.0%) 61 (25.2%) 147 (60.7%) 79.8%
Zambia Centre 2 89 38 (42.7%) 13 (14.6%) 38 (42.7%) 77.4%
Zimbabwe 218 66 (30.3%) 26 (11.9%) 126 (57.8%) 100.0%
https://doi.org/10.1371/journal.pmed.1002775.t002
Table 3. Perinatal outcomes for mothers with antenatal eclampsia, stroke, or hypertensive disorders of pregnancy
causing death or intensive care unit (ICU) admission.
Perinatal outcomes Overall n/N (%)
All stillbirth and neonatal death in women with eclampsia, stroke or ICU admission or
maternal death from hypertensive disorders of pregnancy
625/3,493
(17.9%)
All stillbirth and neonatal death in women with antenatal eclampsia 397/2,495
(15.9%)
Pregnancies ending in stillbirth 322/2,495
(12.9%)
Neonatal death 75/2,495 (3.0%)
All stillbirth and neonatal death in women with hypertensive disorders of pregnancy causing
stroke, ICU admission or death without eclampsia
228/998 (22.8%)
Pregnancies ending in stillbirth 197/998 (19.7%)
Neonatal death 31/998 (3.1%)
Excludes 12 with missing delivery information and 45 that went home after eclampsia without delivery and were not
followed up.
https://doi.org/10.1371/journal.pmed.1002775.t003
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on perinatal outcomes or by age or place of eclampsia are therefore not presented. The effect
of the intervention in individual sites needs further consideration as these are non-randomised
analyses. The numbers of cases of eclampsia and hypertensive disorders of pregnancy were
based on the data reported by attending clinicians in the health facilities; it was not feasible to
undertake additional searching in all sites to identify cases not reported. However, the inclu-
sion of maternal deaths and ICU admissions only from hypertensive disorders of pregnancy
means that misdiagnosis is less likely. Whilst it is a strength that this paper reports magnesium
sulfate availability, this variable was collected on a monthly basis at the level of the facility. As
daily fluctuations in the quantity available or the number of doses prescribed remain
unknown, it is possible that supply may not have been adequate to meet demand.
In the post–Millennium Development Goal era, the focus of global health is on not just
reducing mortality but also reducing morbidity [18]. Yet, in this study, the large variation in
fatality from eclampsia between countries emphasises that both inequality and inequity in
management of hypertensive disorders of pregnancy persist. It has been previously reported
that organ dysfunction is up to 60 times more frequent in women with eclampsia compared to
women without eclampsia [6]. Therefore, the very high rates of maternal death in some coun-
tries compared to previously reported estimates [6,7] highlight that the true burden of disease
in these countries may be even greater than previously recognised and that hypertensive disor-
ders of pregnancy should remain firmly on the global agenda.
This study showed no effect of the CRADLE intervention on eclampsia, stroke, or maternal
death or ICU admission from hypertensive disorders of pregnancy. It is possible that the inter-
vention increased detection but without the capacity to improve management. The primary
purpose of the study was to collect accurate incidence data, and therefore detailed case infor-
mation on clinical management was not routinely collected, given the resource constraints of
the trial. It is challenging therefore to draw conclusions on differences in management that
may also have contributed to variations in the rate of eclampsia and resulting morbidity seen.
However, it is evident that Zambia Centre 1 (Lusaka) had the lowest rate of eclampsia and case
fatality, and admitted substantially more patients to ICU than any other site. This was possible
as they have a specialist unit specifically for women with hypertensive disorders of pregnancy
that provides continuous monitoring and close observation by trained staff. In comparison,
the site in Freetown in Sierra Leone, which had the highest rate of eclampsia and case fatality,
has no higher-level care available. The availability of monitoring to rapidly detect deteriora-
tions—and initiate treatment such as antihypertensives, magnesium sulfate, and timely deliv-
ery—is likely to be important. This idea is in keeping with reports that the largest reductions in
maternal mortality from hypertensive disorders of pregnancy in England and Wales were
achieved with improved surveillance, diagnosis, and timely delivery, with further benefit from
fluid-restriction management protocols and increased use of anticonvulsant therapies in more
recent decades [19].
In this study, nearly a third of eclampsia cases occurred in women aged under 20 years.
This proportion varied greatly between sites, with the Malawi site reporting that half of
eclampsia cases occurred in women aged under 20 years. Other studies have reported rates of
26% [6] to 55% [20]. Whilst this study did not collect demographic data in all deliveries,
nationwide demographic data show that 15% of births in Malawi in 2015–2016 occurred in
women aged under 20 years [21]. Existing literature suggests that teenage pregnant women are
at greater risk of eclampsia [22], and their care should be prioritised in clinical practice. Inter-
ventions aiming to overcome the complex socio-cultural needs of this group to improve access
to healthcare and prevent eclampsia warrant further research.
This study also presents novel data on the place of eclamptic fit, previously only reported
in smaller cohort studies, where 74.5% (n = 142) were reported to occur before hospital
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admission in Latin America [20]. Our data demonstrate that over half of women experience
their first eclamptic fit in a healthcare facility, despite the relatively good availability of magne-
sium sulfate in these settings. However, the proportion of eclampsia cases that first occurred in
healthcare facilities compared to the community varied substantially between sites. This sug-
gests that the most appropriate interventions and strategies to reduce eclampsia should be
informed by local incidence data. For example, in Sierra Leone, Zambia Centre 1, and India,
where a high proportion of eclampsia cases occurred in the community, interventions aiming
to improve community monitoring and overcome barriers to accessing care, including health
education [23], may be the most appropriate use of resources. In contrast, in Uganda Centre 2
and Haiti, targeting the quality of care within facilities may be a more effective strategy for pre-
venting eclampsia. Therefore, when vital actions such as treating severe hypertension with
magnesium sulfate to prevent eclampsia [8] and timely delivery of the baby [10] are recom-
mended, national and international policy makers may also recommend collection of regional
data to identify how these interventions should be delivered to achieve the greatest benefit
locally, thus maximising their impact and identifying the most appropriate use of resources.
In conclusion, this analysis provides accurate contemporaneous estimates of incidence of
eclampsia and hypertensive disorders of pregnancy from the largest known prospective dataset
across 8 low- and middle-resource settings. These data highlight that mortality (for the woman
and baby) from eclampsia remains high, and higher-risk groups exist that should be prioritised
in research and policy. Use of magnesium sulfate to prevent eclampsia and timely delivery
after diagnosis remain important strategies to reduce maternal and perinatal mortality from
hypertensive disorders of pregnancy at the facility level, but interventions should also be tar-
geted to meet the needs of specific regions.
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